In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors

Clinical Cancer Research

Volumn 11, Issue 10, 2005, Pages 3930-3938

  Devi, Gayathri R ^a,c   Beer, Tomasz M ^b   Corless, Christopher L ^b   Arora, Vikram ^a   Weller, Doreen L ^a   Iversen, Patrick L ^a  

^a AVI BIOPHARMA INC   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AVI 4126; UNCLASSIFIED DRUG;

ADULT; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SAFETY; DRUG SPECIFICITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SIDE EFFECT;

ANIMALS; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; FEMALE; GENES, MYC; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICE; MICE, NUDE; MORPHOLINES; PROSTATIC NEOPLASMS;

EID: 18844429452     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2091     Document Type: Article

References (42)

1. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene 2003;22:9007-21.
2. Felsher DW, Bradon N. Pharmacological inactivation of MYC for the treatment of cancer. Drug News Perspect 2003;16:370-4.
3. Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase I safety study in humans. Clin Cancer Res 2003;9:2510-9.
4. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation and properties. Antisense Nucleic Acid Drug Dev 1997;7:187-95.
5. Summerton J, Stein D, Huang SB, Matthews P, Weller D, Partridge M. Morpholino and phosphorothioate oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev 1997;7:63-70.
6. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1999;1489:141-58.
7. Ghosh C, Stein D, Weller D, Iversen PL. Evaluation of antisense mechanisms of action. Methods Enzymol 2000;313:135.
8. Iversen PL. Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr Opin Mol Ther 2001;3:235-8.
9. Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999;1489:69-84.
10. Hudziak RM, Summerton J, Weller DD, Iversen PL. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev 2000;10:163-76.
11. Giles RV, Spiller DG, Clark RE, Tidd DM. Antisense morpholino oligonucleotide analog induces missplicing of c-myc mRNA. Antisense Nucleic Acid Drug Dev 1999;9:213-20.
12. Ricker JL, Mata JE, Iversen PL, Gattone VH. c-myc antisense oligonucleotide treatment ameliorates murine ARPKD. Kidney Int 2002;61 Suppl 1:125-31.
13. Arora V, Knapp DC, Smith BL, et al. c-Myc antisense rat liver regeneration and indicates role for c-myc in regulating cytochrome P-450 3A activity. J Pharmacol Exp Ther 2000;292:921-8.
14. Kipshidze N, Keane E, Stein D, et al. Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv 2001;54:247-56.
15. Iversen PL, Kipshidze N, Moses JW, Leon MB. Local application of antisense for prevention of restenosis. Methods Mol Med 2004;106:37-50.
16. Arora V, Devi GR, Iversen PL. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy, and pharmacokinetics. Curr Pharm Biotechnol 2004;5:431-9.
17. Knapp DC, Mata JE, Reddy MT, Devi GR, Iversen PL. Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in Lewis lung carcinoma murine model. Anti-Cancer Drugs 2003;14:39-47.
18. Devi GR, Oldenkamp JR, London CA, Iversen PL. Inhibition of human chorionic gonadotropin β subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate 2002;53:200-10.
19. Devi GR. Prostate Cancer: Status of current treatments and emerging antisense-based therapies. Curr Opin Mol Ther 2002;4:138-48.
20. Kipshidze NN, Iversen P, Kim HS, et al. Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model. Cardiovasc Radiat Med 2003;4:152-9.
21. Devi GR, Sprenger CC, Plymate SR, Rosenfeld RG. Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo. Prostate 2002;51:141-52.
22. Arora V, Knapp DC, Reddy MT, Weller DD, Iversen PL. Bioavailability and efficacy of antisense morpholino oligomers targeted to c-Myc and cytochrome P-450 3A2 following oral administration in rats. J Pharm Sci 2002;91:1009-17.
23. Shumaker RC. PKCALC: a BASIC interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev 1986;17:331-48.
24. Chan KK, Gibaldi M. Estimation of statistical moments and steady-state volume of distribution for a drug given by intravenous infusion. J Pharmacokinet Biopharm 1982;10:551-8.
25. Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Front Biosci 1998;3:250-68.
26. Hermeking H. The MYC oncogene as a cancer drug target. Curr Cancer Drug Targets 2003;3:163-75.
27. Qian J, Hirasawa K, Bostwick DG, et al. Loss of p53 and c-myc overrepresentation in stage T (2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol 2002;15:35-44.
28. Kaltz-Wittmer C, Klenk U, Glaessgen A, et al. FISH analysis of gene aberrations in advanced prostatic carcinomas before and afterandrogen deprivation therapy. Lab Invest 2000;80:1455-64.
29. Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiprotiferative effects of antiestrogens. Cancer Res 2002;62:3126-31.
30. Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1990;1049:99-125.
31. Pawlak W, Zolnierek J, Sarosiek T, Szczylik C. Antisense therapy in cancer. Cancer Treat Rev 2000;26:333-50.
32. Pirollo KF, Rait A, Sleer LS, Chang EH. Antisense therapeutics: from theory to clinical practice. Pharmacol Ther 2003;99:55-77.
33. Kim R, Tanabe K, Emi M, Uchida Y, Toge T. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer. Int J Oncol 2004;24:5-17.
34. Crooke ST. Progress in antisense technology: the end of the beginning. Methods Enzymol 2000;313:3-45.
35. Crooke RM. In vitro and in vivo toxicology of first generation analogs. In: Crooke ST, Lebleu B, editors. Antisense research and applications. CRC Press, Inc., Boca Raton, FL 1993. p. 471-91.
36. Storey A, Oates D, Banks L, Crawford L, Crook T. Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucleic Acids Res 1991;19:4109-14.
37. Burgess TL, Fisher EF, Ross SL, et al. The antiproliferative activity of c-myb and c-myc antisense oligomers in smooth muscle cells is caused by non-antisense mechanism. Proc Natl Acad Sci U S A 1995;92:4051-5.
38. London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, Devi GR. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 2003;10:823-32.
39. Amantana A, London CA, Iversen PL, Devi GR. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 2004;3:699-707.
40. Ko YJ, Devi GR, London CA, et al. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. J Urol 2004;172:1140-4.
41. Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev 1997;7:503-10.
42. Iversen PL, Cornish KG, Iversen LJ, Mata JE, Bylund DB. Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as α1-adrenergic receptor antagonists. Toxicol Appl Pharmacol 1999;160:289-96.